ArticleAnnals of hematology2025
Hyperhemolysis in a sickle cell disease patient in pregnancy.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Antibody-Dependent and Antibody-Independent Hemolysis in Sickle Cell Disease.Antibodies (Basel, Switzerland) · 2026Review
- Strategies and innovations in hypertension management for sickle cell patients: A narrative review.Medicine · 2026Review
- Tocilizumab provides a potential therapeutic option for the management of hyperhaemolysis syndrome in sickle cell disease: A case series and brief narrative overview of the literature.Transfusion medicine (Oxford, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sickle cell disease (SCD) is the most commonly inherited hemoglobinopathy with the potential for significant maternal and perinatal morbidity and mortality. Hyperhemolysis syndrome (HS) is a rare, and potentially fatal complication of blood transfusion characterized by destruction of both transfused and autologous red blood cells, often resulting in severe anemia with post-transfusion hemoglobin levels lower than pre-transfusion levels. Evidence-based guidance on the prevention and management of HS during pregnancy is limited. We report the case of a 23-year-old gravida 1 para 0 with sickle cell anemia and a history of two prior episodes of HS, successfully managed through a multidisciplinary approach. Her care team included hematologists, maternal-fetal medicine specialists, transfusion medicine pathologists, and neonatologists. Management during pregnancy involved initiating hydroxyurea in the second trimester, implementing a transfusion-restricted protocol, and utilizing immunosuppression and blood conservation strategies. This case highlights the successful application of a multidisciplinary approach to the management of a high-risk pregnancy complicated by SCD and recurrent HS. Key interventions included the use of hydroxyurea, erythropoiesis-stimulating agents, immunosuppression, and a planned delivery strategy, resulting in a favorable maternal and neonatal outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.